Abbott Announces CE Mark for Highly Sensitive Testosterone Test to Measure the Hormone at Low Levels - Aug 28, 2012
New Assay Measures Testosterone Levels to Help Diagnose Related Conditions in Both Males and Females
ABBOTT PARK, Ill., Aug. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today CE Marking (Conformite Europeenne) for a testosterone assay with improved sensitivity and clinical utility. With a simple blood test, the ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.
Abbott Announces CE Mark for Highly Sensitive Testosterone Test to Measure the Hormone at Low Levels - Aug 28, 2012
New Assay Measures Testosterone Levels to Help Diagnose Related Conditions in Both Males and Females
ABBOTT PARK, Ill., Aug. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today CE Mark
ing (Conformite Europeenne) for a testosterone assay with improved sensitivity and clinical utility. With a simple blood test, the ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.